Response to Comments: Trigger Point Injections (TPI) (DL39713)

This article is a response-to-comments summary regarding Draft LCD DL39713 for Trigger Point Injections and does not itself establish clinical coverage criteria. No specific indications, limitations, documentation requirements, or frequency limits are specified in this document; readers should refer to the underlying Draft LCD DL39713 for the formal coverage policy.